POLEN CAPITAL THOUGHT LEADERSHIP June 2015 A L L E RG A N : A H Q C POLENCAPITAL.COM     Executive Summary         The  recent  $70.5  billion  acquisi on  of  Allergan  by  the  Irish  pharmaceu cal  company,  Actavis ...

Pharma’s future has never looked more promising – or more ominous. Major scientific, technological and socioeconomic changes will revive the industry’s fortunes in another decade, but capitalising on these trends will entail making crucial decisions first From vision to decision Pharma 2020 www.pwc.com/pharma2020 Contents Introduction 1 Chapter 1 The best of...

January 2016 Follow @Paul_Hastings Solving The Valuation Puzzle in Life Sciences Transactions: The Pros and Cons of the CVR By David Shine & Samuel Waxman Earnout provisions of all stripes have long populated the private company M&A landscape. But the public company equivalent, contingent value rights (CVRs), has been a much rarer bird. Over the past five years, in the thousands...

life sciences Key Contacts Lisa B. Pensabene New York D: +1­212­326­2077 Ross B. Galin New York D: +1­212­326­4307 Richard Goetz Los Angeles D: +1­213­430­6400 Portia Ku Silicon Valley D: +1...

OUTSIDE PUBLICATION PROPOSED MEDICARE PART B PAYMENT METHODOLOGIES WILL IMPACT DRUG MANUFACTURERS, PHYSICIAN PRACTICES AND HOSPITAL OUTPATIENT DEPARTMENTS BNA'S PHARMACEUTICAL LAW & INDUSTRY REPORT April 22, 2016 AUTHORS AND CONTACTS Donna Lee Yesner On March 11, 2016, the Centers for Medicare & Medicaid Services announced a proposed two-phase demonstration project to test...

Issue 2 – March 2016 IN THIS ISSUE Welcome to the second issue of our EU life sciences alerter that covers some of the most critical developments in the pharmaceutical and medical technology sectors in the last month and is produced by our life sciences lawyers in London, Frankfurt, and Paris. If you have any questions on any of these issues, please contact Paul Ranson. BREXIT...